Disease Landscape and Forecast Insights

Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult…

The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial…

Adult OM/PJI due to MRSA are among the most hard-to-treat MRSA infections due to the difficulties for the body’s natural infection-fighting cells and antibiotics to reach the infected tissues in…

In the context of growing healthcare costs, vaccines stand out as highly cost-effective products for improving public health. Furthermore, compared with pharmaceuticals, vaccines tend to carry a…

Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…

Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…

Human immunodeficiency virus (HIV) is treatment is typically initiated with daily administration of costly yet highly effective antiretroviral therapies from multiple drug classes in order to…

The CMV market targets patients with immunodeficiencies, particularly patients receiving solid organ or hematopoietic stem cell transplants. Current therapies have strong antiviral activity but…

Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs),…

The Human Immunodeficiency Virus (HIV) market is seeing growth due to the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved…

The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern…

China has the greatest burden of hepatitis B and liver cancer in the world. In 2014 chronic hepatitis B virus (HBV) infection affected nearly 89.8 million people in China; we expect the total…